Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Lars Buschhorn(National Center for Tumor Diseases), Diego de Miguel‐Pérez(Mount Sinai Health System), Marzia Del Re(Saint Camillus International University of Health and Medical Sciences), Filip Jankú(The University of Texas MD Anderson Cancer Center), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Adam Wahida(National Center for Tumor Diseases), Andreas Schneeweiß(German Cancer Research Center), Giuseppe Curigliano(European Institute of Oncology), Nagla Abdel Karim(Virginia Cancer Institute), Alessandro Russo(Humanitas University)
Cited by 103
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k